vs
Doximity, Inc.（DOCS）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是Pacira BioSciences, Inc.的1.0倍（$185.1M vs $177.4M），Doximity, Inc.净利率更高（33.3% vs 1.6%，领先31.6%），Doximity, Inc.同比增速更快（9.8% vs 5.0%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs -0.2%）
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
DOCS vs PCRX — 直观对比
营收规模更大
DOCS
是对方的1.0倍
$177.4M
营收增速更快
DOCS
高出4.8%
5.0%
净利率更高
DOCS
高出31.6%
1.6%
两年增速更快
DOCS
近两年复合增速
-0.2%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $185.1M | $177.4M |
| 净利润 | $61.6M | $2.9M |
| 毛利率 | 89.9% | — |
| 营业利润率 | 38.9% | 3.9% |
| 净利率 | 33.3% | 1.6% |
| 营收同比 | 9.8% | 5.0% |
| 净利润同比 | -18.1% | — |
| 每股收益（稀释后） | $0.31 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCSPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $185.1M | $196.9M | ||
| Q3 25 | $168.5M | $179.5M | ||
| Q2 25 | $145.9M | $181.1M | ||
| Q1 25 | $138.3M | $168.9M | ||
| Q4 24 | $168.6M | $187.3M | ||
| Q3 24 | $136.8M | $168.6M | ||
| Q2 24 | $126.7M | $178.0M |
净利润DOCSPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $61.6M | — | ||
| Q3 25 | $62.1M | $5.4M | ||
| Q2 25 | $53.3M | $-4.8M | ||
| Q1 25 | $62.5M | $4.8M | ||
| Q4 24 | $75.2M | — | ||
| Q3 24 | $44.2M | $-143.5M | ||
| Q2 24 | $41.4M | $18.9M |
毛利率DOCSPCRX
| Q1 26 | — | — | ||
| Q4 25 | 89.9% | 79.5% | ||
| Q3 25 | 90.3% | 80.9% | ||
| Q2 25 | 89.2% | 77.4% | ||
| Q1 25 | 89.5% | 79.7% | ||
| Q4 24 | 91.6% | 78.7% | ||
| Q3 24 | 90.0% | 76.9% | ||
| Q2 24 | 89.3% | 75.1% |
营业利润率DOCSPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 38.9% | 1.2% | ||
| Q3 25 | 37.8% | 3.5% | ||
| Q2 25 | 37.4% | 4.7% | ||
| Q1 25 | 35.2% | 1.2% | ||
| Q4 24 | 47.4% | 13.2% | ||
| Q3 24 | 38.8% | -82.8% | ||
| Q2 24 | 36.4% | 15.9% |
净利率DOCSPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | 33.3% | — | ||
| Q3 25 | 36.8% | 3.0% | ||
| Q2 25 | 36.5% | -2.7% | ||
| Q1 25 | 45.2% | 2.8% | ||
| Q4 24 | 44.6% | — | ||
| Q3 24 | 32.3% | -85.1% | ||
| Q2 24 | 32.7% | 10.6% |
每股收益（稀释后）DOCSPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.31 | $0.05 | ||
| Q3 25 | $0.31 | $0.12 | ||
| Q2 25 | $0.27 | $-0.11 | ||
| Q1 25 | $0.31 | $0.10 | ||
| Q4 24 | $0.37 | $0.38 | ||
| Q3 24 | $0.22 | $-3.11 | ||
| Q2 24 | $0.21 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.8M | $144.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $979.3M | $653.9M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOCSPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $64.8M | $238.4M | ||
| Q3 25 | $169.2M | $246.3M | ||
| Q2 25 | $137.3M | $445.9M | ||
| Q1 25 | $209.6M | $493.6M | ||
| Q4 24 | $165.3M | $484.6M | ||
| Q3 24 | $184.2M | $453.8M | ||
| Q2 24 | $111.4M | $404.2M |
总债务DOCSPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益DOCSPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $979.3M | $693.1M | ||
| Q3 25 | $1.1B | $727.2M | ||
| Q2 25 | $1.0B | $757.8M | ||
| Q1 25 | $1.1B | $798.5M | ||
| Q4 24 | $1.0B | $778.3M | ||
| Q3 24 | $961.2M | $749.6M | ||
| Q2 24 | $913.6M | $879.3M |
总资产DOCSPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B |
负债/权益比DOCSPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.9M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 0.99× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOCSPCRX
| Q1 26 | — | — | ||
| Q4 25 | $60.9M | $43.7M | ||
| Q3 25 | $93.9M | $60.8M | ||
| Q2 25 | $62.1M | $12.0M | ||
| Q1 25 | $98.5M | $35.5M | ||
| Q4 24 | $65.2M | $33.1M | ||
| Q3 24 | $68.3M | $53.9M | ||
| Q2 24 | $41.2M | $53.2M |
自由现金流DOCSPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
自由现金流率DOCSPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
资本支出强度DOCSPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | 0.0% | 5.1% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | 0.0% | 0.9% |
现金转化率DOCSPCRX
| Q1 26 | — | — | ||
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | 11.20× | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | 7.37× | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
